Table 2. Comparison the of T1, T2, PD, and ADC values between PCA and benign lesions, between low-risk and intermediate-to-high risk PCA, and between GS upgrade and nonupgrade.
| Pathology | TZ | PZ | PCA risk grade | TTPB GS ≤3+4 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCA (n=61) | BPH (n=96) | P | PCA (n=117) | Inflammation (n=117) | P | GS ≥4+3 (n=116) | GS ≤3+4 (n=62) | P | Upgraded (n=18) |
Nonupgraded (n=50) |
P | ||||
| T1 (msec) | 1,203.83±121.03 | 1,339.37±169.41 | <0.001 | 1,270.27±126.12 | 1,402.80±210.84 | <0.001 | 1,261.52±130.66 | 1,207.00 (1,137.75, 1,275.25) |
0.03 | 1,192.00 (1,112.00, 1,263.75) |
1,287.50 (1,217.25, 1,454.25) |
0.007 | |||
| T2 (msec) | 74.15±8.10 | 80.00 (76.00, 85.00) |
<0.001 | 78.00 (73.00, 82.00) |
88.57±13.60 | <0.001 | 77.00 (73.00, 82.00) |
73.31±7.49 | 0.001 | 73.00 (67.00, 79.00) |
78.00 (75.75, 81.25) |
0.003 | |||
| PD (pu) | 79.22±3.86 | 81.00 (80.00, 84.00) |
<0.001 | 81.00 (78.00, 83.00) |
83.00 (81.00, 85.00) |
<0.001 | 81.00 (78.50, 84.00) |
79.00 (77.00, 81.00) |
0.003 | 79.50 (77.00, 82.00) |
83.50 (78.75, 84.25) |
0.009 | |||
| ADC (×10−6 mm2/s) |
599.22±87.23 | 837.00 (785.50, 907.50) |
<0.001 | 605.74±100.80 | 888.97±160.24 | <0.001 | 580.94±90.10 | 634.50 (604.00, 695.75) |
<0.001 | 636.50 (602.75, 695.00) |
574.00 (528.75, 629.25) |
0.002 | |||
Data following a normal distribution are expressed as the mean ± standard deviation. Otherwise, data are expressed as the median (first quartile, third quartile). PD, proton density; ADC, apparent diffusion coefficient; PCA, prostate cancer; GS, Gleason Score; TZ, transformation zone; PZ, peripheral zone; TTPB, transperineal prostate biopsy; BPH, benign prostatic hyperplasia.